Where we are today is based on what we represent today, while we've been manipulated down dramatically by the MM's etc. until our technology has the respect garnered by approvals a few billions is as much as should be anticipated. Once we have approval, then extending the lives of out patents is huge as that's the time we'll be able to supply the vaccine exclusively.
The end of patents certainly won't end the sales, but it will allow competition, if someone wants to jump into the mix. We'll have the advantage of many EDEN units, and if they too are off patents they could be copied, but anyone wishing to compete would have substantial costs. If we want to keep them out of the business, we're positioned to be cost competitive, it's doubtful they can make the vaccine for less than we can. While our profit per patient may be lower, the numbers may be so great that we simply may not be growing as fast, but we'll still be growing.
How long has Aspirin been off patent. In spite of much higher prices, I suspect Bayer is probably still making more from aspirin sales today than any other time in their history.
I wouldn't mind competing at all if we're the ones supplying personalized vaccines for patients with all types of solid cancers. It will be the investment of a lifetime if the company isn't bought out, and still a great investment if it is.
Gary
News 
Market Data 
Discover 
AI
